SearchBar Icon

Systemic Lupus Erythematosus Pipeline to Witness Many Collaborations in the Coming Years

Published Date:   May 2017

According to a new research report “Systemic Lupus Erythematosus Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments” published by P&S Intelligence, Systemic lupus erythematosus currently exhibits a pipeline with 57 drug candidates.

Explore Report Description at:

Systemic Lupus Erythematosus Exhibits Emerging Pipeline with 50+ Drug Candidates

The study analyzed that the systemic lupus erythematosus pipeline comprises of 57 drug candidates in different stages of development. Systemic lupus erythematosus is a type of lupus in which the immune system damages its own tissues. The disease affects many parts of the body including skin, joints, lungs, brain, blood vessels and kidneys. The systemic lupus erythematosus is caused by impaired immune system due to which the immune system attacks its own tissues and can cause widespread inflammation and tissue damage in the affected organs. Some of the common symptoms of systemic lupus erythematosus include oral ulcers, sun sensitivity, heart problems, kidney problems, psychosis, lung problems, arthritis, seizures, fevers, skin rashes, fatigue, swelling and pain in the joints. Systemic lupus erythematosus is being treated using a combination approach as number of organs are involved. Therefore, various combination therapies are being used to improve quality of life of the patients. Also, combining novel drugs against different organs as well as combination of drugs with biological and biochemical agents may further enhance the treatment quality.

Antibody-drug conjugate (ADC) technology platform for Systemic Lupus Erythematosus drug development

Seattle Genetics, Inc. is using antibody-drug conjugate (ADC) technology platform for the development of Brentuximab vedotin for the treatment of systemic lupus erythematosus. The technology platform employs a monoclonal antibody specific for a tumor-associated antigen, plus synthetic cytotoxic (cell-killing) agents connected by stable linker systems designed to securely bind the cytotoxic agent to the antibody and then release the agent within the targeted cell.

Major companies collaborate for the development of Systemic Lupus Erythematosus Pipeline

The research also found that various companies have collaborated for the development of systemic lupus erythematosus pipeline.

Some of the key players developing drugs for systemic lupus erythematosus include Anthera Pharmaceuticals, Inc., Genentech, Inc., Merck KGaA and others.

Systemic Lupus Erythematosus Pipeline Analysis

  • By Phase
  • By Route of Administration
  • By Target
  • By Company

Send An Enquiry

Secure Lock  By clicking the SUBMIT REQUEST below, you also agree to abide by the Terms and Conditions of the company

Secure Lock  We respect your privacy. Your information will not be shared.